#Sustainability #China #Suzhou #Innovent Biologics #ESG Report

Innovent's Commitment to Sustainability and Innovation in Biopharmaceuticals

Innovent Biologics, a leading biopharmaceutical company, has announced the release of its 2024 Environmental, Social, and Governance (ESG) Report. This comprehensive document not only outlines the company's achievements over the past year but also reaffirms Innovent's steadfast commitment to sustainable development and its role in advancing global healthcare.

The report elaborates on Innovent's strategies across five core pillars: Excellent Governance, Enjoying Good Health, High Quality as Key, People First, and Embracing Ecology. Each of these pillars serves as a foundation for the company's approach to creating value while addressing the pressing challenges of today's world.

Achievements in Governance and Ethics

At the heart of Innovent's sustainability efforts is robust governance. The company has further refined its ESG governance framework to ensure compliance with global standards while remaining agile in responding to industry changes. Key achievements in this area include:

• - Increased Board Diversity: The addition of female directors across the board has been a priority, ensuring that every committee includes at least one female member.
• - Supplier Compliance: Innovent has achieved 100% participation from suppliers regarding its 'Commitment to Compliance.'
• - Training Programs: All employees, including Directors, underwent training sessions focused on compliance, anti-corruption, and business ethics.
• - AAA MSCI ESG Rating: Innovent achieved an MSCI ESG rating of AAA, making it the only biotech from China to receive such recognition and one of only three globally.

Health and Access Innovations

Innovent is particular about bridging health disparities through innovative therapies. With the guiding strategy to discover and globally deliver new medications, the company continues leading in oncology within China. Highlights include:

• - 15 Commercialized Products: These have positively impacted over 5 million patients.
• - New Drug Applications: Innovent is currently working on three new drug applications and multiple clinical trials for chronic diseases.
• - Affordable Medicines: Six of Innovent's medicines are now part of China's National Reimbursement Drug List, improving accessibility and affordability for patients nationwide.
• - Community Support Programs: Efforts in rural education and health initiatives have helped thousands of teachers and students enhance their quality of life.

Quality Assurance in Production

Quality is an unwavering priority for Innovent. The company adheres strictly to internationally recognized production standards and has implemented rigorous quality audits across suppliers. This allows not only for compliance and safety but also for the strengthening of Innovent's position in the global market:

• - Production Capacity: Current production capacity totals 140,000 liters with plans for an increase to 230,000 liters while maintaining 100% GMP-certified facilities.
• - Success Rates: Innovent has maintained a 100% success rate in drug substance manufacturing and passed all audits from regulatory authorities. This commitment to quality enhances the trust in the company’s products.

Empowering Workforce and Talent Development

At the core of Innovent’s success is its workforce. The company prioritizes creating an inclusive and empowering environment:

• - Diversity in Workforce: Women constitute 51% of Innovent's entire workforce and hold 44.2% of management positions.
• - High Retention Rates: The retention rate for key talent stands at an impressive 96.8%, and employee satisfaction is at 98%.
• - Professional Development: With tailored career development pathways, Innovent supports continuous learning and growth, aiming to foster a talent ecosystem that fuels innovative solutions.

Dedication to Environmental Stewardship

Innovent recognizes the need for eco-friendly practices to promote sustainability.

• - ISO Certifications: All production facilities are certified under the ISO 14001 Environmental Management System, emphasizing environmental consciousness in operations.
• - Energy Reduction Initiatives: In the last year, the company achieved a 29% reduction in energy consumption, and water use was reduced by 22%.
• - Climate Action Efforts: Innovent integrates low-carbon principles throughout its operations, setting clear targets for continuous environmental performance improvements.

Conclusion

As Innovent looks to the future, its commitment to global innovation in biopharmaceuticals paired with sustainable practices reaffirms its position as a leader in the industry. The company’s focus on creating a lasting positive impact on health and climate sets a high standard for the biopharmaceutical enterprise. Innovent’s ongoing strategic initiatives will continue to harmonize commercial success with social responsibility, pushing towards a vision of becoming a premier global biopharmaceutical entity.

For further insights about Innovent's objectives and achievements, you can visit their official website.